Large phenotypic variability with severe respiratory involvement in MEGF10-related myopathies: Description of three cases Authors: Alessandra Pennisi, Alexandru Caramizaru, Gianmarco Severa, Damien Sternberg, Andreea Dumitrescu, Corinne Metay, Valerie Biancalana, Robert Yves Carlier, Susana Quijano-Roy, Edoardo Malfatti, Amelia Dobrescu Published: 2026 ABSTRACT MEGF10 biallelic variants cause early-onset myopathy, areflexia, respiratory distress and dysphagia (EMARDD), congenital myopathies with cores, and later-onset myopathies with respiratory failure. As MEGF10 plays a key role in satellite cells proliferation and differentiation, these disorders are considered primary Satellite Cell-opathies. We present clinical, genetic, and laboratory findings from three patients with MEGF10-related myopathy from two families: a 6-year-old boy with EMARDD, and two siblings with a milder myopathy with respiratory involvement. Patient 1, male, showed decreased fetal movements and profound neonatal hypotonia with respiratory failure, requiring tracheostomy soon after birth. At 6 years, he had lack of head and trunk control, scoliosis, and upper limbs antigravity movements. Muscle MRI revealed mild-to-moderate, symmetrical fibro-fatty replacement affecting scapular, paravertebral, gluteal and adductor muscles, with bilateral absence of the semimembranosus. Muscle biopsy revealed a reduction of Pax7-positive satellite cells. Genetic studies disclosed the novel homozygous MEGF10 c.337T>C, p.(Cys113Arg) variant. Patient 2 is a 24-year-old woman with myopathic facies, progressive axial and generalized weakness, and thoracolumbar scoliosis at 11 years, leading to progressive respiratory involvement necessitating tracheostomy at 14 years. Her 17-year-old brother, patient 3, experienced a threatened abortion and perinatal complications consisting of neonatal hypoxia, right arm monoplegia, and clavicle fracture, followed by motor delay, scoliosis and progressive respiratory dysfunction, requiring non-invasive ventilation at 16 years. P2 and P3 harbour the novel homozygous c.917G>C, p. (Arg306Pro) MEGF10 pathogenic variant. We describe three new patients with MEGF10-related myopathy, showing severe but variable clinical expression, associated with two novel variants. Introduction MEGF10 (5q23.2) encodes the transmembrane protein multiple EGF-like domains 10, which is expressed in the spinal cord, brain, and skeletal muscle satellite cells. This protein plays a critical role in mediating apoptosis during cell phagocytosis by binding to the phosphatidylserine expressed on the surface of apoptotic cells; it is also involved in cell adhesion, motility, and proliferation. MEGF10 is essential for satellite cells proliferation. 1 Homozygous or compound heterozygous pathogenic variants in MEGF10 have been linked with congenital core myopathy, 2 also termed Early-onset Myopathy, Areflexia, Respiratory Distress and Dysphagia (EMARDD, MIM 614399) by Logan et al. 3 The main clinical features included generalized hypotonia, respiratory insufficiency due to diaphragmatic involvement, and feeding difficulties. Additional findings included reduced fetal movements, scoliosis, dysphagia, high-arched palate, distal joint contractures, foot deformities, and diaphragmatic eventration. 4 Severely affected individuals often require ventilatory support within the first months or years of life, and in some cases, never achieve independent ambulation. 5 Satellite cells have been extensively studied due to their central role in muscle repair, leading to the identification of several markers, including the transcription factor Pax7, in quiescent satellite cells. 6 MEGF10 itself serves as a marker of quiescent satellite cells, with significant expression in skeletal myoblasts. Experimental modulation of Megf10 alters the expression of Pax7 and myogenic regulatory factors, thereby indicating a role in maintaining the balance between satellite cells proliferation and differentiation. 7 The role of MEGF10 in the satellite cells NOTCH signaling pathway was firstly reported in 2007. 7 To date, MEGF10-related myopathies are considered primary Satellite Cell-opathies.8,9 Here, we report three patients with MEGF10-related myopathy (MEGF10-RM), harboring two novel pathogenic variants. Patients and methods Clinical findings, laboratory results, and molecular genetic data were collected from three patients with MEGF10-RM. Patient 1 (P1) was evaluated and is currently followed at the neuromuscular reference center of Raymond Poincaré Hospital in Garches, France. Patients 2 (P2) and 3 (P3) were diagnosed and assessed at the Regional Center of Medical Genetics Dolj, Craiova, Romania. Clinical features at onset and molecular data are summarized in Table 1, while laboratory findings are shown in Table 2. Management strategies for each patient are highlighted in Table 3. MRI was performed only for patient 1, who also underwent muscle biopsy and satellite cells behavior assessment using the transcription factor Pax7, together with Pax7/Ki67 co-staining to evidence proliferating cells, in comparison with a histologically normal, age-matched muscle.Table 1.Clinical findings.​P1P2P3genetic variantNM_032446.3:c.337T>C p. (Cys113Arg)NM_001256545.2:c.917G>C p. (Arg306Pro)NM_001256545.2:c.917G>C (p.Arg306Pro)onsetneonatalchildhoodneonatalsexmalefemalemaleconsanguinityyesyesyesantenatal signsyesunknownrisk of spontaneous abortion at 5 months of gestationneonatal hypotoniayesunknownunknownrespiratory failureyesyesyesscoliosisyesyesyesdysphagiayesnonojoint hyperlaxitynononoophthalmoplegianononocontracturesnounknownelbow and ankle contracturesTable 2.Clinical and paraclinical parameters.​P1P2P3BMI Kg/m211,98 (4 yo)17,7 (17 yo)11.5 (12 yo)CKNormalNA424 UI/LFVCNANA31% (1,26L)pCO249mmHgNA47 mmHgmuscle biopsylipid overload in type I fibers, large unevenness in the fiber size with rounded edgesNANoMRI signsnormal brain; agenesis of the semimembranosus muscle on the left and atrophic on the right; diffuse amyotrophy and predominant axial and upper limbs fatty infiltrationNAdextroconcave thoraco-lumbar scoliosis; anomaly of lumbo-sacral vertebral transition Castelli IIb leftEMGmyogenic in proximal muscles, no decrement, neurogenic lesion in face –right armNAchronic muscle damage; axonal polyneuropathyEMG: electromyography.Table 3.Therapeutic management.P1P2P3tracheostomy; chronic mechanical ventilation; bethanechol; salbutamoltracheostomy; chronic mechanical ventilationBiPAP; T4-S2 AI posterior spondylosynthesis under robotic guidance Table 1.Clinical findings.​P1P2P3genetic variantNM_032446.3:c.337T>C p. (Cys113Arg)NM_001256545.2:c.917G>C p. (Arg306Pro)NM_001256545.2:c.917G>C (p.Arg306Pro)onsetneonatalchildhoodneonatalsexmalefemalemaleconsanguinityyesyesyesantenatal signsyesunknownrisk of spontaneous abortion at 5 months of gestationneonatal hypotoniayesunknownunknownrespiratory failureyesyesyesscoliosisyesyesyesdysphagiayesnonojoint hyperlaxitynononoophthalmoplegianononocontracturesnounknownelbow and ankle contractures Clinical findings. Table 2.Clinical and paraclinical parameters.​P1P2P3BMI Kg/m211,98 (4 yo)17,7 (17 yo)11.5 (12 yo)CKNormalNA424 UI/LFVCNANA31% (1,26L)pCO249mmHgNA47 mmHgmuscle biopsylipid overload in type I fibers, large unevenness in the fiber size with rounded edgesNANoMRI signsnormal brain; agenesis of the semimembranosus muscle on the left and atrophic on the right; diffuse amyotrophy and predominant axial and upper limbs fatty infiltrationNAdextroconcave thoraco-lumbar scoliosis; anomaly of lumbo-sacral vertebral transition Castelli IIb leftEMGmyogenic in proximal muscles, no decrement, neurogenic lesion in face –right armNAchronic muscle damage; axonal polyneuropathyEMG: electromyography. Clinical and paraclinical parameters. EMG: electromyography. Table 3.Therapeutic management.P1P2P3tracheostomy; chronic mechanical ventilation; bethanechol; salbutamoltracheostomy; chronic mechanical ventilationBiPAP; T4-S2 AI posterior spondylosynthesis under robotic guidance Therapeutic management. Patient 1 underwent whole genome sequencing at the Genetic Center of Pitié-Salpêtrière, Paris – Multisite Medical Biology Laboratory. P2 and P3 underwent whole exome sequencing (Regional Center of Medical Genetics Dolj, Craiova), and multi-gene panel sequencing (neuromuscular disorders panel – Invitae, USA), respectively. Results Patient 1 P1 is a male child born to consanguineous Algerian parents (Figure 1(a)). His mother reported reduced fetal movements during pregnancy. Delivery required vacuum-assisted extraction due to non-progressive labor, and was followed by immediate neonatal resuscitation, including stimulation, suctioning, and several minutes of ambu-bag ventilation. Apgar score was 2/6/8. Birth weight was 3,520 g. Head circumference was normal. At six hours of life, clinical examination showed profound hypotonia and absent sucking reflexes. He was admitted to a neonatal intensive care unit, where he received CPAP for six days, and nasogastric feeding for several weeks. A maternal-foetal group B Streptococcus (GBS) infection was also documented. A thin corpus callosum was noted on a brain MRI in the first day of life.Figure 1.Family trees.Figure 1 Family trees for patient 1 (a), and patients 2 and 3, respectively (b). Patients 2 and 3, siblings, had similar evolutions, exhibiting a significantly milder myopathy phenotype compared to P1 while still developing severe scoliosis and respiratory impairment. P2 and P3 have two paternal first cousins (brothers) with scoliosis and pectus carinatum, respectively. Family trees. Figure 1 Family trees for patient 1 (a), and patients 2 and 3, respectively (b). Patients 2 and 3, siblings, had similar evolutions, exhibiting a significantly milder myopathy phenotype compared to P1 while still developing severe scoliosis and respiratory impairment. P2 and P3 have two paternal first cousins (brothers) with scoliosis and pectus carinatum, respectively. At four months of age, the patient had not yet achieved head control and exhibited severe hypotonia, areflexia, thoracic scoliosis and pectus excavatum. No craniofacial dysmorphism was observed, except for a high-arched palate. Electromyographic examination revealed a myopathic pattern. The respiratory course was severe, with high-flow nasal cannula (HFNC) required by 2 months due to complete unilateral lung atelectasis, which recurred at 4 months in the context of an RSV (respiratory syncytial virus) infection. This episode was complicated by respiratory arrest and a right-sided pneumothorax, necessitating endotracheal intubation. Following several unsuccessful extubation attempts, the patient was transferred to an ICU. Computed tomography confirmed a complete diaphragmatic paralysis. Extubation was achieved at 6 months of age; however, the patient remained dependent on continuous non-invasive nasal ventilation (24h/day), and subsequently underwent tracheostomy and gastrostomy at nine months of age. By the age of six years, the patient remained fully dependent on assisted ventilation via tracheostomy, and required a Garches brace due to severe cervico-axial hypotonia. Head and trunk control were absent. Bulbar dysfunction was profound, with complete reliance on gastrostomy for nutrition. He did not develop oral language, and used pictograms to communicate. In contrast to the severe axial weakness, the patient was able to move his arms against gravity. Patient 2 P2 is a young female born to consanguineous Romanian (Figure 1(b)) parents after an uneventful pregnancy. Family history revealed the presence of two paternal first cousins with scoliosis and pectus carinatum, respectively. She had a normal psychomotor development, with thoraco-lumbar scoliosis appearing at 11 years of age and contributing to a progressive impairment of the respiratory function. Tracheostomy was performed at 14 years of age (Table 3). Clinical evaluation at 17 years of age showed a BMI of 17.7 (40 kg, 150 cm), a discrete myopathic facies, hypotonia, and a very severe scoliosis (Figure 2(a)).Figure 2.Physical characteristics of the three patients.Figure 2 Photographs of the affected individuals showing scoliosis and tracheostomy for patient 2 at 24 years (a, b, c); Poland Syndrome before and after Z-plasty and scoliosis for patient 3 at 10 years (d, e, f); respiratory support for patient 1 at 1 year (g) and 5 years (h). Physical characteristics of the three patients. Figure 2 Photographs of the affected individuals showing scoliosis and tracheostomy for patient 2 at 24 years (a, b, c); Poland Syndrome before and after Z-plasty and scoliosis for patient 3 at 10 years (d, e, f); respiratory support for patient 1 at 1 year (g) and 5 years (h). Patient 3 P3 is the younger brother of P2. The pregnancy came to medical attention at approximately 20 weeks due to a threatened abortion. At birth, he presented hypoxia, monoplegia of the right arm, and a right clavicle fracture followed by developmental delay. A mild thoracic-lumbar scoliosis appeared at eight years. Physical examination at ten years of age revealed a facial dysmorphism (microcephaly – cranial circumference 49 cm, myopathic facies, hypertelorism, elongated palpebral slants, broad nasal root, long philtrum, high-arched palate, micrognathia) and a Poland sequence anomaly for which a Z-plasty was performed (Figure 2(d)–(f); Figure 3(a)–(d)). A growth deficit was also documented later (at 12 yo, 24 kg, 144 cm, BMI 11.5). EMG at 12 years of age showed a myopathic pattern and a radiculopathy. Periodical pulmonary assessments evidenced a progressive restrictive respiratory dysfunction, with a forced vital capacity (FVC) at 30% of predicted value at 16 years of age, requiring the use of a BiPAP machine.Figure 3.Patient 3 Spinal x-ray: spinal fusion surgery at age 16.Figure 3 Patient 3 Spinal x-ray before (a, b) and after spinal fusion surgery (c, d). Thoracic-lumbar scoliosis had appeared at 8 years of age. Patient 3 Spinal x-ray: spinal fusion surgery at age 16. Figure 3 Patient 3 Spinal x-ray before (a, b) and after spinal fusion surgery (c, d). Thoracic-lumbar scoliosis had appeared at 8 years of age. Neuromuscular examination at 16 revealed a global and significant muscle atrophy, neck flexor weakness, elbow and ankle contractures, and a severe scoliosis needing spinal fusion surgery (also performed at 16). Table 4 summarizes previously reported cases of MEGF10-RM.Table 4.Published MEGF10 cases.Study (year, journal)Patients (n)Variants reported (examples; HGVS as given)Phenotype/muscle biopsyAge at onsetRespiratory involvementNotesLogan et al., 2011 (Nat Genet) 3 10 (5 families)Truncating + missense (incl. nonsense/frameshift; cysteine substitutions in EGF-like domains); p.Trp520X, p.Asp766EfsX4, p.Cys767X, p.Tyr1048X, p.Pro442HfsX9, p.Cys774ArgClassic EMARDD: neonatal hypotonia, areflexia; biopsy often non-specificNeonatal/infantileEarly ventilatory support commonFirst description linking MEGF10 to EMARDDBoyden et al., 2012 (Neurogenetics) 1 3 siblings (+1 single-het)Compound het missense in EGF-like cysteines (e.g., p.Cys326Arg + p.Cys774Arg)Multiminicore features; axial/proximal weakness, scoliosisChildhoodRestrictive defect; NIV in someEstablished association with minicoresPierson et al., 2013 (Neuromuscul Disord) 10 1Homozygous exon 7 deletion (∼757 bp)Severe EMARDD; marked fatty replacement on MRI/biopsyNeonatalEarly ventilator dependenceGross deletion in MEGF10Takayama et al., 2016 (Neuromuscul Disord) 11 Case seriesNovel missense variants; p.Val44Alafs*9, p.Cys810Tyr, c.2981-2A>GCongenital myopathy with variable cores/myofibrillar changesChildhoodVariableProposed genotype–phenotype correlationsLiewluck et al., 2016 (Muscle & Nerve) 8 2 (sisters)Compound het missense (e.g., p.Arg77Gln + p.Cys611Trp)Adult-onset multiminicore myopathy; biopsy with multiminicoresAdulthood (5th decade)Prominent respiratory insufficiencyExpanded spectrum to late-onset mvEMARDDHarris et al., 2018 (Neuromuscul Disord) 9 1 (+ review ∼20 cases)c.1426+1G>T (splice) + p.Cys118Arg (missense)Myofibrillar aggregation; variable coresAdultProminent respiratory failureNull vs missense correlationSaha et al., 2019 (Hum Mol Genet) 12 Clinical/cell report-Core-like/whorled fibers appearing on later biopsyChildhood → laterVariableEarly biopsies may be non-specificAlMuhaizea et al., 2021 (Genes) 13 2 (unrelated)c.3132dupA (frameshift, hom); c.2980+5G>C (splice, hom)One severe EMARDD (death at 8m); one milder axial myopathySince birthSevere in one; mild in otherIncludes Table S1 of prior variantsCroci et al., 2022 (Acta Myol) 14 1p.Cys699Ser (hom missense)Progressive mvEMARDD; minicores + myofibrillar alterationsInfancy → progressiveNIV from adolescenceSummarizes ∼23 patientsFujii et al., 2022 (Neuromuscul Disord) 15 1 (+review)Novel MEGF10 mutation, p.G739RmvEMARDD; truncating vs missense severity gradientVariableVariableFurther genotype–phenotype detailFigueiredo et al., 2024 (Cureus) 16 1MEGF10 pathogenic variant, p.Arg71Trp; VUS, p.Arg77TrpSevere scoliosis as clue; EMARDD phenotypeChildhoodProgressive restrictive defectScoliosis-first presentationThis study (Pennisi et al., 2025; JND)3p.Cys113Arg (novel, hom); p.Arg306Pro (hom; upgraded)P1: severe EMARDD; P2–P3: milder with scoliosis; P1 biopsy: reduced Pax7+ cellsP1: neonatal; P2: childhood; P3: neonatalP1: tracheostomy from birth; P2: trach at 14 y; P3: BiPAPNovel cysteine variant; Arg306Pro reclassified; supports satellite cell-opathy Table 4.Published MEGF10 cases.Study (year, journal)Patients (n)Variants reported (examples; HGVS as given)Phenotype/muscle biopsyAge at onsetRespiratory involvementNotesLogan et al., 2011 (Nat Genet) 3 10 (5 families)Truncating + missense (incl. nonsense/frameshift; cysteine substitutions in EGF-like domains); p.Trp520X, p.Asp766EfsX4, p.Cys767X, p.Tyr1048X, p.Pro442HfsX9, p.Cys774ArgClassic EMARDD: neonatal hypotonia, areflexia; biopsy often non-specificNeonatal/infantileEarly ventilatory support commonFirst description linking MEGF10 to EMARDDBoyden et al., 2012 (Neurogenetics) 1 3 siblings (+1 single-het)Compound het missense in EGF-like cysteines (e.g., p.Cys326Arg + p.Cys774Arg)Multiminicore features; axial/proximal weakness, scoliosisChildhoodRestrictive defect; NIV in someEstablished association with minicoresPierson et al., 2013 (Neuromuscul Disord) 10 1Homozygous exon 7 deletion (∼757 bp)Severe EMARDD; marked fatty replacement on MRI/biopsyNeonatalEarly ventilator dependenceGross deletion in MEGF10Takayama et al., 2016 (Neuromuscul Disord) 11 Case seriesNovel missense variants; p.Val44Alafs*9, p.Cys810Tyr, c.2981-2A>GCongenital myopathy with variable cores/myofibrillar changesChildhoodVariableProposed genotype–phenotype correlationsLiewluck et al., 2016 (Muscle & Nerve) 8 2 (sisters)Compound het missense (e.g., p.Arg77Gln + p.Cys611Trp)Adult-onset multiminicore myopathy; biopsy with multiminicoresAdulthood (5th decade)Prominent respiratory insufficiencyExpanded spectrum to late-onset mvEMARDDHarris et al., 2018 (Neuromuscul Disord) 9 1 (+ review ∼20 cases)c.1426+1G>T (splice) + p.Cys118Arg (missense)Myofibrillar aggregation; variable coresAdultProminent respiratory failureNull vs missense correlationSaha et al., 2019 (Hum Mol Genet) 12 Clinical/cell report-Core-like/whorled fibers appearing on later biopsyChildhood → laterVariableEarly biopsies may be non-specificAlMuhaizea et al., 2021 (Genes) 13 2 (unrelated)c.3132dupA (frameshift, hom); c.2980+5G>C (splice, hom)One severe EMARDD (death at 8m); one milder axial myopathySince birthSevere in one; mild in otherIncludes Table S1 of prior variantsCroci et al., 2022 (Acta Myol) 14 1p.Cys699Ser (hom missense)Progressive mvEMARDD; minicores + myofibrillar alterationsInfancy → progressiveNIV from adolescenceSummarizes ∼23 patientsFujii et al., 2022 (Neuromuscul Disord) 15 1 (+review)Novel MEGF10 mutation, p.G739RmvEMARDD; truncating vs missense severity gradientVariableVariableFurther genotype–phenotype detailFigueiredo et al., 2024 (Cureus) 16 1MEGF10 pathogenic variant, p.Arg71Trp; VUS, p.Arg77TrpSevere scoliosis as clue; EMARDD phenotypeChildhoodProgressive restrictive defectScoliosis-first presentationThis study (Pennisi et al., 2025; JND)3p.Cys113Arg (novel, hom); p.Arg306Pro (hom; upgraded)P1: severe EMARDD; P2–P3: milder with scoliosis; P1 biopsy: reduced Pax7+ cellsP1: neonatal; P2: childhood; P3: neonatalP1: tracheostomy from birth; P2: trach at 14 y; P3: BiPAPNovel cysteine variant; Arg306Pro reclassified; supports satellite cell-opathy Published MEGF10 cases. Muscle MRI (patient 1) The main imaging findings are illustrated in Figure 4. The scapular girdle showed mild-to-moderate bilateral and symmetrical involvement (Mercuri 2-3) of the supraspinatus, infraspinatus, trapezius and deltoid muscles. An axial involvement was noted in the form of moderate, symmetric fibro-fatty replacement of paravertebral muscles at the dorsal and lumbar levels, predominantly affecting the rotatores spinae (Figure 4(c)), and leading to secondary right convex thoracic scoliosis (Figure 4(d), star). In the pelvic girdle, a bilateral and symmetric involvement of gluteus muscles (Figure 4(e), star) and adductors (Figure 4(f), arrow) was observed. In the lower limbs, a striking feature was the bilateral absence of semimembranosus muscles (Figure 4(g), arrowhead), while other proximal and distal muscles were relatively preserved.Figure 4.Whole body muscle MRI from patient 1.Figure 4 Whole body muscle MRI showing T2 Dixon axial images (a, b, c, f, g, h) and T2 Dixon coronal images (d, e). Diffuse muscle hypotrophy. (b, c) Bilateral and symmetric involvement of rotators spinae at dorsal and lumbar level (arrow). (d) Right-convex thoracic scoliosis (star). (e) Bilateral symmetric involvement of glutei (star). Symmetric and bilateral involvement of adductors (f arrow). Bilateral absence of semimembranosus (g arrowhead). Globally preserved muscles at leg level (h). Whole body muscle MRI from patient 1. Figure 4 Whole body muscle MRI showing T2 Dixon axial images (a, b, c, f, g, h) and T2 Dixon coronal images (d, e). Diffuse muscle hypotrophy. (b, c) Bilateral and symmetric involvement of rotators spinae at dorsal and lumbar level (arrow). (d) Right-convex thoracic scoliosis (star). (e) Bilateral symmetric involvement of glutei (star). Symmetric and bilateral involvement of adductors (f arrow). Bilateral absence of semimembranosus (g arrowhead). Globally preserved muscles at leg level (h). Myopathological findings (patient 1) Two muscle biopsies were obtained from patient 1, at 6 months and 15 months of age, respectively. Both showed unspecific myopathic findings including important fiber size variability and moderate lipid droplets content augmentation in type 1 fibers. Of note, there was a mild increase of endomysial connective tissue. No muscle biopsies were available for P2 and P3. Genetics P1 karyotype, Prader-Willi and myotonic dystrophy type 1 testing were negative. Whole genome sequencing disclosed a homozygous MEGF10 missense variant of uncertain significance, NM_001256545.2:c.337T>C, p. (Cys113Arg), in exon 6 (Table 1). This novel variant is absent from gnomAD (v4.1.0); it has a high CADD phred score (29.70), and it is consistently predicted as damaging/pathogenic by multiple algorithms (SIFT, PolyPhen-2, AlphaMissense, REVEL, ClinPred). 17 P1 also harbors a COL6A2 (NM_001849.4:c.1970-9G>A) intronic variant previously reported in patients carrying biallelic pathogenic COL6A2 variants, 18 not in keeping with the patient’s phenotype. Genetic analyses of P2 and P3 disclosed the presence of the novel NM_001256545.2:c.917G>C, p. (Arg306Pro), homozygous MEGF10 variant. This variant has a very low frequency in gnomAD v4.1.0 (allele count 2, no homozygotes), and a high CADD phred score (35.00); spliceAI predicts a donor site loss, and multiple missense predictors classify it as damaging/pathogenic. 16 Satellite cells studies on muscle biopsy (patient 1) Immunofluorescence studies showed a higher number of satellite cells (Pax7+) but no activated satellite cells (Pax7+/Ki67+) in the control compared with patient P1, consistent with the absence of necrosis and regeneration. In contrast, P1 exhibited a markedly reduced number of Pax7-positive cells, along with increased activation, indicating impaired satellite cell behavior and supporting the classification of MEGF10-RM as a satellite cell-opathy (Figure 5).Figure 5.Satellite cells studies on P1 muscle biopsy.Figure 5 (a) Immunofluorescence of muscle section from patient 1. DAPI (nuclei in blue), Pax7 (red), Ki67 (green) Grey Arrows: nucleus/Pax7; Yellow Arrows: nucleus/Pax7/Ki67. (a′) Quantification of the different myogenic stains showing prominent PAX7 positive cells reduction in P1 (1) and their activation (2). Satellite cells studies on P1 muscle biopsy. Figure 5 (a) Immunofluorescence of muscle section from patient 1. DAPI (nuclei in blue), Pax7 (red), Ki67 (green) Grey Arrows: nucleus/Pax7; Yellow Arrows: nucleus/Pax7/Ki67. (a′) Quantification of the different myogenic stains showing prominent PAX7 positive cells reduction in P1 (1) and their activation (2). Discussion MEGF10-related conditions are clinically heterogeneous in terms of severity and onset, with adulthood presenting cases also reported.13,14 For this reason, we suggest the term of MEGF10-RM. Our patients showed features similar to previously reported MEGF10-RM patients,1,3,12,19 with P1 exhibiting a particularly severe phenotype. Similar phenotypes have been described, including prenatal onsets with reduced fetal movements or cases leading to death in the first year of life. 10 P1 received antibiotics treatment for a maternal–foetal group B Streptococcus (GBS) infection in the immediate neonatal period; despite clinical improvement of intercurrent issues, profound hypotonia and ventilatory dependence persisted. Therefore, a transient contribution to the initial respiratory distress cannot be entirely excluded. Nevertheless, given the lifelong course and the later demonstration of complete diaphragmatic paralysis, we consider GBS an intercurrent perinatal factor rather than a causal element. At 5 months, the weakness pattern in P1 was relatively atypical compared to other congenital myopathies, 20 with better proximal strength (quadriceps and deltoids quoting 4/5 MRC) and distal hands and feet muscular weakness. In regard to the thin corpus callosum, central nervous system structural anomalies are not a recognized feature of MEGF10-RM, which primarily affects satellite cells and skeletal muscles. In the absence of other consistent neurological signs, we interpret this finding as incidental. Nonetheless, because MEGF10 is also expressed in the brain, we cannot entirely exclude the correlation of this finding with MEGF10; longitudinal neurodevelopmental follow-up is warranted. Patients 2 and 3, siblings, had similar evolutions, with P3 also exhibiting a neurodevelopmental delay. Both developed severe scoliosis and respiratory impairment: P2 required tracheostomy, whereas P3 underwent spinal fusion and uses non-invasive ventilation. These differences likely reflect their ages at diagnosis and the limited care access during their early history. P1 muscle biopsies showed non-specific changes, with a mild connective tissue increase consistent with earlier reports. Previous studies have described histological alterations including fatty tissue replacement, increased connective tissue, regenerating fibers, fiber-size variation, moth-eaten fibers and minicores.1,10 In some cases, an initially non-specific biopsy was followed by a later biopsy revealing myofibrillar myopathy patterns with cores, inclusions, and whorled fibers. 12 In patient 1, we did not observe important differences between the two muscle biopsies. Very importantly, we demonstrated a reduction in Pax7 positive satellite cells in P1 muscle (Figure 5), as well as an important activation of these cells, suggesting a dysregulation of myogenesis and supporting the concept of MEGF10-RM as a satellite cell-opathy. 8 Our satellite cells findings are in-keeping with other data from the literature, 3 although reports of normal Pax7 expression in MEGF10-RM patients exist. 7 MEGF10-RM muscle MRI data remain scarce in the literature. In one early-onset case with a homozygous exon 7 deletion, a marked involvement of gluteal and quadriceps muscles was observed, with near-complete fatty replacement, while hamstring and gracilis muscles were relatively spared, 5 similarly to the pattern of involvement found in P1 (Figure 4). The bilateral absence of the SM muscles is a particular aspect, resembling another Primary Satellite Cell-opathy, Rigid Spine Muscular Dystrophy 1, associated with SELENON variants, where a severe atrophy of SM muscles is reported. 21 Importantly, differential diagnosis includes other Primary Satellite Cell-opathies, as well as spinal muscular atrophy with respiratory distress (SMARD1), which may mimic MEGF10-RM through early diaphragmatic weakness and respiratory failure.4,22 The homozygous MEGF10 c.337T>C, p. (Cys113Arg), missense variant found in P1 affects a highly conserved cysteine within an EGF-like domain, where cysteine residues form disulfide bridges. Cysteine substitutions in EGF-like domains are among the most common MEGF10 variants,1,3,11–14 and are thought to interfere with the tyrosine phosphorylation activity. 23 A pathogenic variant involving a neighboring cysteine, (p.Cys118Arg), has been reported in a patient with milder, adult-onset disease. 13 The variant has a heterozygous status in each parent, further supporting the pathogenic role of p. Cys113Arg. The homozygous MEGF10 missense variant identified in patients 2 and 3, NM_001256545.2:c.917G>C, p. (Arg306Pro), although classified as VUS in some platforms (Franklin, InterVar), is considered likely pathogenic in others (VarSome, GeneBe). Its homozygous status in both affected siblings strongly supports a pathogenic effect. 24 Genotype–phenotype correlations remain evolving. Previous studies suggest that missense variants are often associated with a later onset, while null variants usually cause early respiratory dysfunction.13,25 However, early disease onset has also been observed in patients with biallelic missense variants, as well as in P1 (Table 4, MEGF10 cases summary). P1 also carried a heterozygous intronic variant in COL6A2 (NM_001849.4:c.1970-9G>A), previously associated with recessive collagen VI-related muscular dystrophies.15,18,26 No second variant was identified (either SNV or CNV), and the phenotype was not consistent with a collagen VI myopathy. Interestingly, collagen secretion studies in fibroblasts revealed intracellular retention and a reduced collagen VI network compared to healthy controls (Supplementary Figure 1). Although these findings likely reflect an incidental carrier status, we do not entirely exclude the possibility of an interaction between MEGF10 and extracellular matrix or COL6 secretion. COL6A2 is part of a group of genes linked with Secondary Satellite Cell-opathies, with biallelic pathogenic variants affecting both satellite cells and muscle fibres. 8 However, further evidence would be necessary to determine whether an interaction between MEGF10 and COL6A2 could influence the phenotype. In our case series, axial involvement led to severe scoliosis with secondary thoracic deformity, further aggravating respiratory function. This disproportionate respiratory impairment, requiring tracheostomy or non-invasive ventilation while patients are still ambulant (Figure 2(a)–(c), patient 2), is a relatively distinctive feature of MEGF10-RM. Few other myopathies show a similar pattern, such as SELENON-related congenital myopathies with dorsal hyperlordosis and trunk shift, 27 or late-onset Pompe disease, where severe respiratory dysfunction can occur in ambulant patients, usually due to primary diaphragmatic involvement rather than thoracic deformities. 28 Conclusion MEGF10-RM exhibits a broad phenotypic spectrum. Although many cases follow a moderate course, some individuals, such as patient 1, present with severe forms with prenatal onset. Here we enlarge the genetic spectrum reporting two novel pathogenic variants. Early and tailored management of complications, including progressive scoliosis requiring surgical intervention, may help reduce the respiratory burden and improve quality of life. Further studies are needed to clarify MEGF10-RM natural history and to identify prognostic markers. Supplemental material Supplemental material - Large phenotypic variability with severe respiratory involvement in MEGF10-related myopathies: Description of three cases Supplemental material for Large phenotypic variability with severe respiratory involvement in MEGF10-related myopathies: Description of three cases by Alessandra Pennisi, Alexandru Caramizaru, Gianmarco Severa, Damien Sternberg, Andreea Dumitrescu, Corinne Metay, Valerie Biancalana, Robert Yves Carlier, Susana Quijano-Roy, Edoardo Malfatti, and Amelia Dobrescu in Journal of Neuromuscular Diseases.